Stay updated with breaking news from Stephen Hurly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 -- LAVA Therapeutics N.V. , a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of...
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembr
LAVA Therapeutics NV (NASDAQ:LVTX) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK) to evaluate its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with LAVA-1207 in patients with therapy refractory metastatic castration-resistant prostate cancer. Under the terms of the agreement, Merck will provide pembrolizumab for the dose escalation and expansion phases of LAVA’s ongoing Phase 1/2a study of LAVA-1207, with the combination arm expec
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 -- LAVA Therapeutics N.V. ; class='js-l-obf link link--blue'
Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The... | June 8, 2023